Photodynamic Therapy for Oral Precursor Lesions (PDT)
A Randomized Controlled Trial: Photodynamic Treatment for the Therapy of Premalignant Mucosal Oral Lesions.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
-
Vienna, Austria, 1090
- Bernhard Gottlieb University clinic of Dentistry
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Existing Leukoplakia simplex SIN III (diagnostics by Biopsie)
- Leukoplakia verrucosa without indications of malignant changes (diagnostics by Biopsie)
- Oral Lichen planus SIN III (diagnostics by Biopsie)
- Good mouth hygiene status (tartar, surface)
- Correct seat of the prosthesis and/or the denture
- Located erosions in the oral cavity
- Minimum age:18 years
- Women at the age capable of child-bearing with an appropriate contraception
Exclusion Criteria:
- Malignant changes of the mucous membrane, heavy Dysplasie SIN III, Carcinoma in situ - heavy vitamin deficiency
- Pregnancy
- less than 18
- Satisfying women
- No tobacco abuse
- satisfying therapy with local immunmodulators in lichen ruber
- surgical therapy of leukoplakia indicated
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: DOUBLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
PLACEBO_COMPARATOR: Placebo
|
Methylcellulose
|
|
EXPERIMENTAL: Aminolaevulinic acid
|
Photodynamic therapy
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes in percent (%) of the initial area in mm2 assessed on recall appointment and by a blinded examiner on photographs with a caliper.
Time Frame: each treatment average once a week, recall after 4 weeks
|
each treatment average once a week, recall after 4 weeks
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
pain due to treatment, assessed by visual analogue scale (VAS)
Time Frame: each treatment, average once a week
|
each treatment, average once a week
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Director: Gabriella Dvorak, PD, DMD, MD, Medical University Vienna
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 2010_MuSH
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.